Among the drugs in the Antibody Drug Conjugates (ADC), Adcetris will witness faster growth than Kadcyla

Date: 25 March 2017

Over the recent years, the global antibody drug conjugates industry has been growing rapidly as the global sales of Adcetris and Kadcyla have been witnessing rapid growth after their approval. Globally, the growth in the antibody drug conjugates market is driven by large number of ADC drugs in pipeline, rise in global incidences of cancer and wider therapeutic window offered by ADCs.

According to Azoth Analytics research report, “GlobalAntibody Drug Conjugates  (ADC) Market –Analysis By Drugs  (Adcetris, Kadcyla),Pipeline Drugs, Regulations: Opportunities and Forecasts (2017-2022)”, global market is projected to display a robust growth represented by a CAGR of 21.82% during 2017 – 2022, chiefly driven by large number of ADC drugs in pipeline, rising number of cancer patients and wider therapeutic window offered by antibody drug conjugates.

Globally, only two ADCs are present in the market – Adcetris and Kadcyla. Adcetris was approved by FDA in 2011 and Kadcyla in 2013. Mylotarg, a drug developed by Pfizer, was the first ADC ever approved but was voluntarily withdrawn from the market in 2010 but is still available in Japan. Approval and successful commercialization of Adcetris and Kadcyla have made the biopharmaceutical market realise the immense potential that ADC holds. There has been heavy investment in the development of ADCs by leading biotechnology and biopharmaceutical companies with about 50 molecules presently in the clinical development stage and more than 190 trials taking place around the world. Several molecules are currently in late stage of clinical trials and are expected to gain approval and enter market in next few years which will result in heavy growth of global ADC market. Companies have been strategically expanding their market through multiple licensing of proprietary ADC technology, and collaboration amongst companies for developing ADCs. Major trend that the ADC market has been witnessing over the years is outsourcing of ADC production to CMOs (Contract Manufacturing Organisation)  

Among the drugs, Adcetris will witness faster growth than Kadcyla as the former is expecting approval for more indications in the forecasted period. Among the regions, North America is predicted to advance at the highest rate, mainly driven by increase in several ADC molecules expected to gain FDA approval in next few years

The report titled “GlobalAntibody Drug Conjugates  (ADC) Market –Analysis By Drugs  (Adcetris, Kadcyla),Pipeline Drugs, Regulations: Opportunities and Forecasts (2017-2022)” has covered and analysed the potential of Global Antibody Drug Conjugates Market and provides statistics and information on market size, shares and growth factors. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment evaluation. Besides, the report also identifies and analyses the emerging trends along with major drivers, challenges and opportunities in the global food service equipment market. Additionally, the report also highlights market entry strategies for various companies across the globe.

A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Global Antibody Drug Conjugates Market on the basis of Analysis By Drug (Adcetris, Kadcyla), Pipeline Analysis (Developer, Phase, Indication, Status, Cytotoxic Payload, Linker, Target), By Region (North America, Europe, APAC and ROW) and By Country (U.S., Canada, U.K., Germany, France, China, India, Japan, Singapore, Brazil and South Africa).

...